268 related articles for article (PubMed ID: 33457261)
1. Tumor heterogeneity in muscle-invasive bladder cancer.
Kang HW; Kim WJ; Choi W; Yun SJ
Transl Androl Urol; 2020 Dec; 9(6):2866-2880. PubMed ID: 33457261
[TBL] [Abstract][Full Text] [Related]
2. Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy.
da Costa JB; Gibb EA; Nykopp TK; Mannas M; Wyatt AW; Black PC
Urol Oncol; 2022 Jul; 40(7):287-294. PubMed ID: 30528886
[TBL] [Abstract][Full Text] [Related]
3. New horizons in bladder cancer research.
Boormans JL; Zwarthoff EC; Black PC; Goebell PJ; Kamat AM; Nawroth R; Seiler R; Williams SB; Schmitz-Dräger BJ
Urol Oncol; 2020 Dec; 38(12):867-885. PubMed ID: 30852032
[TBL] [Abstract][Full Text] [Related]
4. Single-Cell Proteomic Analysis Dissects the Complexity of Tumor Microenvironment in Muscle Invasive Bladder Cancer.
Feng C; Wang X; Tao Y; Xie Y; Lai Z; Li Z; Hu J; Tang S; Pan L; He L; Wang Q; Li T; Mo Z
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771607
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma.
Kang HW; Kim WJ; Yun SJ
Transl Cancer Res; 2020 Oct; 9(10):6609-6623. PubMed ID: 35117271
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
Verghote F; Poppe L; Verbeke S; Dirix P; Albersen M; De Meerleer G; Berghen C; Ost P; Villeirs G; De Visschere P; De Man K; De Maeseneer D; Rottey S; Van Praet C; Decaestecker K; Fonteyne V
BMC Cancer; 2021 Oct; 21(1):1113. PubMed ID: 34663254
[TBL] [Abstract][Full Text] [Related]
7. De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity.
Moosavi SH; Eide PW; Eilertsen IA; Brunsell TH; Berg KCG; Røsok BI; Brudvik KW; Bjørnbeth BA; Guren MG; Nesbakken A; Lothe RA; Sveen A
Genome Med; 2021 Sep; 13(1):143. PubMed ID: 34470666
[TBL] [Abstract][Full Text] [Related]
8. Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer.
Huang HM; Li HX
Cancer Commun (Lond); 2021 Feb; 41(2):91-108. PubMed ID: 33377623
[TBL] [Abstract][Full Text] [Related]
9. The molecular limitations of biomarker research in bladder cancer.
Vlachostergios PJ; Faltas BM
World J Urol; 2019 May; 37(5):837-848. PubMed ID: 30171455
[TBL] [Abstract][Full Text] [Related]
10. Comparative bioinformatics analysis of prognostic and differentially expressed genes in non-muscle and muscle invasive bladder cancer.
Silva TA; Azevedo H
J Proteomics; 2020 Oct; 229():103951. PubMed ID: 32860965
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer.
Boegemann M; Krabbe LM
Mini Rev Med Chem; 2020; 20(12):1133-1152. PubMed ID: 27173513
[TBL] [Abstract][Full Text] [Related]
12. Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer.
Sirab N; Drubay D; Maillé P; Popova T; Ngo C; Gentien D; Moktefi A; Soyeux-Porte P; Pelletier R; Reyes C; Henry E; Pouessel D; Vordos D; Lebret T; de Reyniès A; Paoletti X; Radvanyi F; Allory Y
J Pathol; 2022 Jan; 256(1):108-118. PubMed ID: 34611919
[TBL] [Abstract][Full Text] [Related]
13. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
14. Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA.
Morera DS; Hasanali SL; Belew D; Ghosh S; Klaassen Z; Jordan AR; Wang J; Terris MK; Bollag RJ; Merseburger AS; Stenzl A; Soloway MS; Lokeshwar VB
J Urol; 2020 Jan; 203(1):62-72. PubMed ID: 31112107
[TBL] [Abstract][Full Text] [Related]
15. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
[TBL] [Abstract][Full Text] [Related]
16. Integrative Transcriptomic, Lipidomic, and Metabolomic Analysis Reveals Potential Biomarkers of Basal and Luminal Muscle Invasive Bladder Cancer Subtypes.
Feng C; Pan L; Tang S; He L; Wang X; Tao Y; Xie Y; Lai Z; Tang Z; Wang Q; Li T
Front Genet; 2021; 12():695662. PubMed ID: 34484294
[TBL] [Abstract][Full Text] [Related]
17. Identification of an immunotherapy-responsive molecular subtype of bladder cancer.
Song BN; Kim SK; Mun JY; Choi YD; Leem SH; Chu IS
EBioMedicine; 2019 Dec; 50():238-245. PubMed ID: 31735557
[TBL] [Abstract][Full Text] [Related]
18. Classification of Muscle Invasive Bladder Cancer to Predict Prognosis of Patients Treated with Immunotherapy.
Wang Z; Li X; Wang X; Liu J; Wang L; Wei W; Duan X; Ding D
J Immunol Res; 2022; 2022():6737241. PubMed ID: 35677536
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
[TBL] [Abstract][Full Text] [Related]
20. Identification of prognostic biomarkers associated with stromal cell infiltration in muscle-invasive bladder cancer by bioinformatics analyses.
Li P; Cao J; Li J; Yao Z; Han D; Ying L; Wang Z; Tian J
Cancer Med; 2020 Oct; 9(19):7253-7267. PubMed ID: 32786144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
